Blog

Nelson Advisors partner Lloyd Price has been acknowledged in the Exploration of Digital Health Technologies publication 'A call for responsible innovation in pediatric health care.'Source: <a href="https://www.explorationpub.com/Journals/edht/Article/101178" data-mce-href="https://www.explorationpub.com/Journals/edht/Article/101178">https://www.explorationpub.com/Journals/edht/Article/101178</a>AcknowledgmentsWe gratefully acknowledge Lloyd Price, BA (Hons.), Partner at Nelson Advisors LLP, London, UK, for his editorial feedback and comments on early drafts of this manuscript.A call for responsible innovation in pediatric health careArtificial intelligence (AI) is transforming healthcare by equipping clinicians and patients with tools that support more efficient, patient-centered care. In pediatrics, however, the implementation of AI demands a higher threshold for responsibility, transparency, and family-centered engagement. This perspective explores the opportunities and challenges of AI in pediatric healthcare, highlighting the unique ethical and developmental considerations that distinguish children’s care from adult medicine. Drawing on Kaiser Permanente’s seven principles for responsible AI, the article emphasizes the importance of augmentation over automation, the need for pediatric-specific validation, and the necessity of trustworthiness and fairness in clinical deployment. It outlines how AI can support primary care providers through enhanced decision support, early screening for developmental and behavioral disorders, including the potential for AI to create personalized developmental trajectories, moving beyond static population norms to provide earlier, more precise insights into a child’s neurodevelopmental progress, improved electronic health record usability, and risk prediction models. However, without careful governance, AI poses risks of bias, inequity, and erosion of clinician judgment. Policy recommendations include redesigning family consent models, ensuring robust clinician training, and mandating pediatric-specific testing of AI systems with diverse, representative datasets. Ultimately, AI should function as a supportive tool that strengthens, not replaces, human empathy, clinical expertise, and family-centered values. Responsible innovation is essential to ensure that children benefit equitably from AI while maintaining trust, safety, and compassion in pediatric healthcare.

Nelson Advisors acknowledged in the Exploration of Digital Health Technologies publication

Nelson Advisors has been referenced by Clear Capital Markets in their 'MedPal AI: Looking to bulk up the price on weight-loss drive' Broker Note.Source: <a href="https://www.clearcapitalmarkets.co.uk/analysis/medpal-ai-broker-note" data-mce-href="https://www.clearcapitalmarkets.co.uk/analysis/medpal-ai-broker-note">https://www.clearcapitalmarkets.co.uk/analysis/medpal-ai-broker-note</a>Valuations Medpal EV/Revenue multiple of between 6-8x for the 1Y forward period37“Dominance of AI and Digital Health: AI is the single biggest driver of valuation premiums. Investors and strategic buyers are focusing on companies with proprietary AI algorithms for diagnostics, drug discovery, or patient care. They are particularly interested in solutions that have been clinically validated and are deeply integrated into existing clinical workflows, creating "workflow lock-in."” Nelson Advisers.Note 37 <a href="https://nelsonadvisors.co.uk/blog/european-medtech-valuation-multiples---september-2025">https://nelsonadvisors.co.uk/blog/european-medtech-valuation-multiples---september-2025</a> &nbsp;nelsonadvisors.co.uk/blog/european-medtech-valuation-multiples---september-2025Clear Capital MarketsClear Capital Markets is a proud member of the London Stock Exchange Authorised and regulated by the Financial Conduct Authority. FRN: 706689AI × Robotic Powered Healthcare Ecosystem&nbsp; Sometimes there are businesses where the plan is so in the sweet spot and the management is so focused on the opportunity that they progress at a speed which the market at large confuses with a mixed message.Medpal AI from inception was always about creating a powerful Telehealth vertical and they spotted the opportunity, and grasped it, to enter into the clinical dispensing layer of the healthcare model with the Universal Pharmacy deal4.From inception, and reviewing their business at IPO, it was obvious to us that MPAL is at the cutting edge of the AI interface. They are all about disrupting models but with a purpose. Too many devices, apps, fragmented data. Healthcare markets and insurers disjointed, all in an era where information and science have never been so prolific and advanced.The UK market for health is broken. Speak to most people about the NHS system and trying to access their doctor and the lucky ones will have an appointment in two weeks time. Pharmacies are closing or going out of business (over 1,000 since 202638). Manual dispensing has a 2% error rate and chronic disease management is an after thought. This is why the online pharmacy /Telehealth model is growing so quickly.The first incarnation of Medpal had already identified the data disconnect problem. 1.4bn people globally using digital health tools40, with over 50% of UK adults owning a wearable device41 but with so few joined options where the data leads you down the chain to healthcare delivery. Medpal would look to solve this with the app that was device and operating system agnostic and partnerships to move you down the vertical to telehealth practitioners.Medpal has evolved significantly in a short space of time. The goal of making wellness and healthcare instantly accessible and affordable for everyone is still the aim and with a focus on rebuilding the UK system. They should be at the front end of this as they have actually moved down the vertical and are focused on patient interaction now. Effectively they are now solving patient healthcare needs and reversing them into health management. The technology platform combined with robotic automation puts Medpal in the upper quadrant of offerings and built to outperform at scale.&nbsp;The routes to the MedPal ecosystem have expanded beyond the app to medpal.clinic and WhatsApp interaction with a clinician-trained AI.Focusing data and behaviours into a centralised dispensing model with 24/7 clinical support and delivery nationwide within a day. They have reached incredible scale in a short time without short-cuts in a regulated health market trying its best to remove bad actors whilst improving customer outcomes.

Nelson Advisors referenced by Clear Capital Markets in their MedPal AI Broker Note

The global healthcare landscape in 2030 is defined by a paradigm shift from reactive, episode-based care to proactive, continuous health management facilitated by the industrialisation of artificial intelligence. At the vanguard of this transformation is Anthropic’s Claude ecosystem, which has successfully transitioned from a collection of generative models into a foundational clinical infrastructure.&nbsp; &nbsp;&nbsp; The trajectory of this development was dictated not merely by increases in raw computational power, but by a strategic emphasis on safety-first alignment, interoperability through open standards and a deep integration into the regulated workflows of life sciences and clinical practice.&nbsp; &nbsp;&nbsp; By 2030, the healthcare AI market, which was valued at approximately $36.67 Billion in 2025, has expanded at a compound annual growth rate (CAGR) of nearly 39% as health systems reallocate capital toward platforms that demonstrate recurring value through clinical defensibility and administrative throughput.The integration of Anthropic’s Claude into the 2030 healthcare ecosystem represents more than a technological upgrade; it is the realisation of a patient-centred, data-driven medical frontier. By positioning itself as the "Safety-first" partner for regulated industries, Anthropic has moved beyond the "inference resale" model to become an indispensable layer of the modern clinic.&nbsp; &nbsp;&nbsp; The focus on Constitutional AI has provided the necessary guardrails for high-stakes decision-making, while open standards like MCP have dissolved the silos that once paralysed medical data. &nbsp;&nbsp; As we look toward the 2030s, the challenge for healthcare leaders is no longer to adopt AI faster but to build the organizational capabilities required to sustain and scale it safely. The winners of this era are those who have successfully integrated AI into their core workflows, transforming it from a novelty into a "brilliant friend" with the knowledge of a doctor and the precision of a computer.&nbsp; &nbsp;&nbsp; In this environment, Claude serves not as a replacement for human judgment but as its most powerful amplifier, ensuring that the complexity of human biology is navigated with intelligence, empathy, and an unwavering commitment to safety.Click here to read our Blog Post <a href="https://www.healthcare.digital/single-post/the-orchestration-of-clinical-intelligence-anthropic-claude-and-the-healthcare-ecosystem-in-2030">https://www.healthcare.digital/single-post/the-orchestration-of-clinical-intelligence-anthropic-claude-and-the-healthcare-ecosystem-in-2030</a>Nelson AdvisorsTo discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a>

Anthropic Claude and the Healthcare Ecosystem in 2030

Nelson Advisors have been invited to the House of Commons for the launch of the UCL GBSH Societal Impact Report on May 6th 2026.Hosted by Baroness Gisela Stuart, the evening will showcase the achievements of UCL Global Business School for Health in advancing its mission and vision across education, research, innovation and partnership.It will also recognise the organisations and some of the individuals whose collaboration has helped make that progress possible, while looking ahead to the next chapter of impact in global healthcare.Source: <a href="https://www.linkedin.com/posts/uclgbsh-healthcareleadership-globalhealth-share-7455287187753025536-tXBu/">https://www.linkedin.com/posts/uclgbsh-healthcareleadership-globalhealth-share-7455287187753025536-tXBu/</a>The UCL Global Business School for Health (GBSH) is the first business school in the world totally dedicated to health and healthcare management. Established in 2021, it was born out of the realisation, amplified by the COVID-19 pandemic, that health systems worldwide desperately need better leadership, management, and innovation to remain sustainableSource: <a href="https://www.ucl.ac.uk/population-health-sciences/global-business-school-health">https://www.ucl.ac.uk/population-health-sciences/global-business-school-health</a>

Nelson Advisors have been invited to the House of Commons for the launch of the UCL GBSH Societal Impact Report

The final week of April 2026 has been a high-stakes period for European HealthTech, dominated by critical regulatory deadlines for AI and medical devices, alongside a surge in "sovereign" digital infrastructure.Here are the major developments from this week:⚖️ Regulatory "Hardening" &amp; AI ComplianceThe biggest story this week is the AI Act Omnibus negotiations reaching a fever pitch.Trilogue Deadlines: On April 28, the final scheduled trilogue session took place. While broad alignment exists to delay some high-risk AI enforcement until December 2027, the core transparency requirements for new Generative AI systems are still set to trigger on August 2, 2026. MDR Integration: There is a definitive shift toward governing AI medical devices under existing sectoral laws (MDR/IVDR) rather than creating a separate "AI-only" regulatory loop. This aims to prevent manufacturers from being buried under redundant paperwork. EUDAMED Countdown: The European Commission confirmed that mandatory use of the first four modules of the Eudamed database will begin in May 2026. Companies have been in a "data-cleansing" frenzy this week to meet the registration requirements. 💰 Funding &amp; Strategic Investments European Commission Injection: On April 21, the Commission opened seven Digital Europe Programme calls worth €63.2 million.€9 million is earmarked specifically for AI-powered cancer and cardiovascular screening. €24 million is dedicated to the European Health Data Space (EHDS) to unlock cross-border health data. Early-Stage Impact: The UK’s largest early-stage impact VC, Eka Ventures, closed a €91.5 million Fund II this month, targeting pre-seed startups in healthcare and sustainable wellbeing. Robotics &amp; Longevity: The European Innovation Council (EIC) awarded €118 million to 30 deep-tech projects, with a massive focus on modular surgical robotics and "healthy ageing" biotech. 🏥 Infrastructure &amp; Market Shifts Sovereign Cloud Adoption: A major trend solidified this week as Becton Dickinson (BD) launched its Pyxis Proand Incada platforms in Europe using the AWS European Sovereign Cloud. This allows hospitals to scale digital tools while strictly adhering to EU data sovereignty laws. The "Health Companion" NHS App: IBM was awarded a £160 million contract to transform the NHS App into a proactive health companion. It will now integrate personalized data and AI adherence tools, moving away from being a simple appointment portal. Irish R&amp;D Hub: Boston Scientific announced a €75 million expansion in Galway this week, focusing on next-gen cardiovascular therapies, while Isla Health launched its European HQ in Ireland to drive clinical informatics across the EU. 🤖 Clinical Technology Cera’s AI Lab: Home care giant Cera launched a dedicated AI lab on April 16 (scaling up operations this week) to develop tools that predict patient deterioration, aiming to slash hospital readmissions by identifying risks before a crisis occurs. Robotic Milestones: CMR Surgical announced its Versius Plus platform has surpassed 40,000 procedures, marking a significant milestone for European-grown surgical robotics competing against US incumbents. &nbsp; Key Takeaway: The "wild west" era of digital health pilots is ending. Between the MHRA–NICE Aligned Pathway in the UK and the EU AI Act deadlines, the market is now prioritizing "evidence-first" technologies that can integrate directly into hospital EHRs with high-level cybersecurity (SOC 2/HITRUST) certification.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a href="mailto:lloyd@nelsonadvisors.co.uk" data-mce-href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a>&gt;&gt;&gt;&gt;&nbsp;The final week of April 2026 has been a high-stakes period for European MedTech, dominated by critical regulatory shifts, the launch of a new "Breakthrough" pathway, and a surge in surgical robotics milestones.Here are the major developments from this week:⚖️ Regulatory Overhaul: MDR &amp; IVDR Simplification The biggest news this week (April 27–30) is the formal move by the European Commission and Parliament to "harden" the regulatory framework while simultaneously easing administrative burdens.The "Omnibus" Negotiations: On April 28, the final scheduled trilogue session for the AI Act Omnibus took place. While broad alignment exists to delay enforcement for high-risk AI embedded in medical devices until August 2, 2028, the transparency requirements for new Generative AI models remain set for August 2, 2026. Targeted MDR/IVDR Reforms: The Commission has proposed eight key areas of reform to prevent device shortages. Notably, the requirement for a Permanently Available PRRC (Person Responsible for Regulatory Compliance) is being eased for SMEs, and certain "legacy" device evidence categories are being expanded to keep essential products on the market.EUDAMED Countdown: This week triggered a "data-cleansing" frenzy as the Commission confirmed the mandatory use of the first four EUDAMED modules will begin in May 2026.🚀 Launch of the "Breakthrough" Pilot On April 28, 2026, the European Commission, the EMA, and the MDCG launched a Breakthrough Medical Device Pilot.Accelerated Access: This initiative mimics the US FDA’s Breakthrough Designation. It provides manufacturers of highly innovative tech (like neuro-implants and advanced robotics) with priority scientific advice and a streamlined pathway to clinical validation.&nbsp;Strategic Shift: This marks a pivotal turn from Europe being a "compliance-only" market to one that actively incentivizes cutting-edge hardware to solve unmet medical needs.&nbsp;🤖 Robotics &amp; Clinical Milestones CMR Surgical: The British-born robotics giant announced this week that its Versius Plus platform has surpassed 40,000 procedures. The company is currently rolling out an advanced digital analytics suite across Europe ahead of a major US push later this year. J&amp;J MedTech: Following the Heart Rhythm Society (HRS) meeting this week, J&amp;J announced the European launch of the VARIPULSE Pro3, a next-gen pulsed field ablation (PFA) system for atrial fibrillation.Automated Suturing: The Israeli/European firm Nitinotes completed its first commercial procedures in Spain for the EndoZip™ system, the first automated suturing tool for endoscopic gastroplasty to reach the Spanish market.💰 Funding &amp; Infrastructure Horizon Europe Calls: New HORIZON-HLTH-2026 calls opened this week, specifically targeting "Regulatory Science" for patient-centered tech and the development of New Approach Methodologies (NAMs) to replace animal testing in device validation.UK "Indefinite" Recognition: The MHRA’s consultation on the indefinite recognition of CE-marked devices in Great Britain concluded this week. This move is expected to provide long-term stability for European manufacturers selling into the UK market.Sovereign Cloud Pivot: Major players like Becton Dickinson (BD) are increasingly moving their European platforms (like Pyxis Pro) onto Sovereign Cloud infrastructures to comply with the sharpening Data Governance Act requirements.&nbsp;Key Takeaway: The industry is currently in a "race to register" for EUDAMED while navigating a complex transition where AI regulations are being folded directly into the MDR/IVDR framework to avoid double-regulation.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a>

This Week in European MedTech and HealthTech: 1st May 2026

Nelson Advisors has been quoted in the MedTech World 'Healthcare 2026: Why resilience trumps caution in the AI era' article discussing risk, AI and the IPO potetial of various healthcare technology companies.Source: <a href="https://med-tech.world/news/healthcare-2026-why-resilience-trumps-caution-in-the-ai-era/">https://med-tech.world/news/healthcare-2026-why-resilience-trumps-caution-in-the-ai-era/</a>Innovation Versus Resilience: The False Trade-OffBoth the Deloitte survey and Nelson Advisors’ IPO predictions emphasize resilience as organizations navigate uncertainty. But resilience isn’t achieved through caution—it’s built through practice.As companies grow larger, they tend to become more risk-averse. They reward not taking risks, which atrophies the resilience muscle. In product development, I consistently see larger organizations being too conservative. Some fraction of every budget must fund the innovation side of the business, or you become obsolete.This is where the IPO market dynamics become fascinating. Nelson Advisors predicts 2026 will mark “The Return of the Mega-Deal,” with large healthcare IPOs like Zelis Healthcare (projected at $1B+ valuation) and potential Medtronic MiniMed spin-offs entering the market. Companies demonstrating measurable AI ROI are particularly attractive.But here’s the challenge: after an IPO, public scrutiny intensifies dramatically. I’ve been in startups that went public, then bought themselves back private—twice—because managing investors while managing the business proved nearly impossible.Amazon cracked this code by telling investors upfront: “We’re going to waste this big chunk of change every year trying innovative things.” As long as they manage both the business and the narrative, it works. In medtech, I haven’t seen anyone successfully balance both. Most bigger companies avoid any scent of risk, which tamps innovation down and they just repeat what worked last year and wonder why their performance is lagging that of their “worthy rivals”.The Competitive Divide Is Widening Companies not using AI in their development processes and daily operations will be bypassed by startups and competitors who do. This isn’t hypothetical. I’m watching it happen in real-time.In 2025 alone, we’ve moved from chaotic AI experimentation to sophisticated automation using tools like Claude Code. The teams I work with in my biweekly executive roundtable are experiencing radical capability increases with the same headcount and hours in the day.The startups entering the IPO pipeline understand this. According to Nelson Advisors’ watchlist, companies like Sword Health (digital MSK care, $4B valuation) and Maven Clinic (women’s and family health, $1.7B valuation) are positioning for liquidity events precisely because they’ve integrated AI into their operational DNA.Meanwhile, established companies debate whether AI is worth the investment.Sources: Deloitte: 2026 Life Sciences Outlook SurveyNelson Advisors. “HealthTech, Digital Health, MedTech IPO Predictions 2026<a href="https://www.healthcare.digital/single-post/healthtech-digital-health-medtech-ipo-predictions-2026">https://www.healthcare.digital/single-post/healthtech-digital-health-medtech-ipo-predictions-2026﻿</a>

Nelson Advisors

Blog

Nelson Advisors acknowledged in the Exploration of Digita...

Nelson Advisors referenced by Clear Capital Markets in th...

Anthropic Claude and the Healthcare Ecosystem in 2030

Nelson Advisors have been invited to the House of Commons...

This Week in European MedTech and HealthTech: 1st May 2026

Nelson Advisors quoted in MedTech World 'Healthcare 2026:...